ArticleLab animal2022
The genomic landscape of canine diffuse large B-cell lymphoma identifies distinct subtypes with clinical and therapeutic implications.
Article in Lab animal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 26 citations in OpenAlex.
- Establishment of Patient-Derived Xenotransplant and Cell Line Models for Canine B-Cell Lymphoma.Cells · 2026Article
- Prognostic impact of TP53 mutations in diffuse large B-cell lymphoma.Annals of hematology · 2026Article
- Diagnosis and Classification of Primary Nodal Lymphomas in Dogs: A Consensus of the Oncology-Pathology Working Group.Veterinary and comparative oncology · 2025Review
- Expanding the Spectrum of Canine Diffuse Large B-Cell Lymphoma Genetic Aberrations Through Whole Genome Sequencing Analysis.Veterinary and comparative oncology · 2025Article
- Identification of novel genetic mutations for the treatment prognostication of canine lymphoma.NPJ precision oncology · 2025Article
- Characterization of the genomic landscape of canine diffuse large B-cell lymphoma reveals recurrent H3K27M mutations linked to progression-free survival.Scientific reports · 2025Article
- Comprehensive investigation of gene mutations in canine large cell gastrointestinal lymphoma.Frontiers in veterinary science · 2025Article
- PI3Kδ activation, IL-6 overexpression, and CD37 loss cause resistance to naratuximab emtansine in lymphomas.Blood advances · 2024Article
- Predictive value ofThe veterinary quarterly · 2024Article
- Investigation of the mutations in the genes involved in Janus kinase/signal transducer and activator of transcription pathway in canine large cell gastrointestinal lymphoma.The Journal of veterinary medical science · 2024Article
- Comprehensive Analysis of Microsatellite Instability in Canine Cancers: Implications for Comparative Oncology and Personalized Veterinary Medicine.Animals : an open access journal from MDPI · 2024Article
- The K9 lymphoma assay allows a genetic subgrouping of canine lymphomas with improved risk classification.Scientific reports · 2024Article
- Thinking Outside the Box: Indirect Myc Modulation in Canine B-Cell Lymphoma.Animals : an open access journal from MDPI · 2024Article
- Exploratory screening for micro-RNA biomarkers in canine multicentric lymphoma.Frontiers in veterinary science · 2024Article
- Leading the pack: Best practices in comparative canine cancer genomics to inform human oncology.Veterinary and comparative oncology · 2023Review
- Article
- TRAF3: A novel regulator of mitochondrial physiology and metabolic pathways in B lymphocytes.Frontiers in oncology · 2023Review
- Article
- The diagnostic relevance of mesenteric lymph node biopsy in small intestinal lymphoma in cats.Journal of veterinary internal medicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 6 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoid neoplasm in dogs and in humans. It is characterized by a remarkable degree of clinical heterogeneity that is not completely elucidated by molecular data. This poses a major barrier to understanding the disease and its response to therapy, or when treating dogs with DLBCL within clinical trials. We performed an integrated analysis of exome (n = 77) and RNA sequencing (n = 43) data in a cohort of canine DLBCL to define the genetic landscape of this tumor. A wide range of signaling pathways and cellular processes were found in common with human DLBCL, but the frequencies of the most recurrently mutated genes (TRAF3, SETD2, POT1, TP53, MYC, FBXW7, DDX3X and TBL1XR1) differed. We developed a prognostic model integrating exonic variants and clinical and transcriptomic features to predict the outcome in dogs with DLBCL. These results comprehensively define the genetic drivers of canine DLBCL and can be prospectively utilized to identify new therapeutic opportunities.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.